JP2018535196A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535196A5
JP2018535196A5 JP2018516843A JP2018516843A JP2018535196A5 JP 2018535196 A5 JP2018535196 A5 JP 2018535196A5 JP 2018516843 A JP2018516843 A JP 2018516843A JP 2018516843 A JP2018516843 A JP 2018516843A JP 2018535196 A5 JP2018535196 A5 JP 2018535196A5
Authority
JP
Japan
Prior art keywords
amino acid
heavy chain
domain
antibody
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018516843A
Other languages
English (en)
Japanese (ja)
Other versions
JP7239320B2 (ja
JP2018535196A (ja
Filing date
Publication date
Priority claimed from EP15188060.6A external-priority patent/EP3150637A1/en
Application filed filed Critical
Priority claimed from PCT/EP2016/073410 external-priority patent/WO2017055539A1/en
Publication of JP2018535196A publication Critical patent/JP2018535196A/ja
Publication of JP2018535196A5 publication Critical patent/JP2018535196A5/ja
Application granted granted Critical
Publication of JP7239320B2 publication Critical patent/JP7239320B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018516843A 2015-10-02 2016-09-30 多重特異性抗体 Active JP7239320B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15188060.6 2015-10-02
EP15188060.6A EP3150637A1 (en) 2015-10-02 2015-10-02 Multispecific antibodies
EP16168918 2016-05-10
EP16168918.7 2016-05-10
PCT/EP2016/073410 WO2017055539A1 (en) 2015-10-02 2016-09-30 Multispecific antibodies

Publications (3)

Publication Number Publication Date
JP2018535196A JP2018535196A (ja) 2018-11-29
JP2018535196A5 true JP2018535196A5 (cg-RX-API-DMAC10.html) 2019-11-07
JP7239320B2 JP7239320B2 (ja) 2023-03-14

Family

ID=57068100

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018516843A Active JP7239320B2 (ja) 2015-10-02 2016-09-30 多重特異性抗体

Country Status (5)

Country Link
US (3) US20170129962A1 (cg-RX-API-DMAC10.html)
EP (1) EP3356420B1 (cg-RX-API-DMAC10.html)
JP (1) JP7239320B2 (cg-RX-API-DMAC10.html)
CN (1) CN108290958B (cg-RX-API-DMAC10.html)
WO (1) WO2017055539A1 (cg-RX-API-DMAC10.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
JP5768147B2 (ja) 2011-02-28 2015-08-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 一価抗原結合タンパク質
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
ES2788979T3 (es) 2014-11-14 2020-10-23 Hoffmann La Roche Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de TNF
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
MA41375A (fr) 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
JP6996979B2 (ja) 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3150636A1 (en) * 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
EP3589650A1 (en) 2017-03-02 2020-01-08 Novartis AG Engineered heterodimeric proteins
US11161911B2 (en) 2017-10-23 2021-11-02 Go Therapeutics, Inc. Anti-glyco-MUC1 antibodies and their uses
CA3084398A1 (en) * 2018-01-15 2019-07-18 I-Mab Biopharma Us Limited Modified c.kappa. and ch1 domains
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
WO2019183406A1 (en) * 2018-03-21 2019-09-26 Invenra Inc. Multispecific antibody purification with ch1 resin
JP7541930B2 (ja) 2018-06-29 2024-08-29 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｍｕｃ１抗体およびその使用
US20220089722A1 (en) * 2018-12-29 2022-03-24 Nantong Yichen Biopharma. Co. Ltd. Heterodimeric fusion protein
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CA3248133A1 (en) 2022-01-24 2023-07-27 Novimmune Sa COMPOSITION AND METHODS FOR THE SELECTIVE ACTIVATION OF CYTOKINE SIGNALING PATHWAYS
WO2023174925A1 (en) 2022-03-14 2023-09-21 Novimmune Sa Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
EP4493593A1 (en) * 2022-03-18 2025-01-22 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof
US20250333484A1 (en) 2022-04-14 2025-10-30 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Bispecific antibodies to ebola virus glycoprotein and their use
AU2023268051A1 (en) 2022-05-13 2025-01-02 BioNTech SE Rna compositions targeting hiv
CA3277013A1 (en) * 2022-12-14 2024-06-20 Evolveimmune Therapeutics, Inc. BISPECIFIC ANTIBODY FUSION MOLECULES AND THEIR METHODS OF USE
WO2024138151A1 (en) 2022-12-22 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees
CN121127490A (zh) 2022-12-28 2025-12-12 生物技术欧洲股份公司 靶向hiv的rna组合物
CN121866336A (zh) 2023-08-03 2026-04-14 百欧恩泰欧洲股份公司 靶向hiv的rna组合物
EP4754130A2 (en) 2023-08-03 2026-06-10 BioNTech SE Rna compositions targeting hiv
WO2025098100A1 (en) * 2023-11-07 2025-05-15 Biomap (Suzhou) Intelligent Technology Limited Modified polypeptides for heteromultimer
WO2026068864A1 (en) 2024-09-30 2026-04-02 BioNTech SE Engineered ch1 and cl domains for the prevention of chain mispairing

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE102005028778A1 (de) * 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US7642282B2 (en) * 2007-01-19 2010-01-05 Milliken & Company Whitening agents for cellulosic substrates
EP3663318A1 (en) * 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JP2014511836A (ja) 2011-03-25 2014-05-19 グレンマーク ファーマシューティカルズ， エセ．アー． ヘテロ二量体免疫グロブリン
KR101261949B1 (ko) * 2011-05-13 2013-05-13 현대자동차주식회사 촉매유닛
US8901853B2 (en) * 2012-07-11 2014-12-02 Analog Devices, Inc. Multi-string LED drive system
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
PL3092251T3 (pl) * 2014-01-06 2021-08-02 F. Hoffmann-La Roche Ag Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg

Similar Documents

Publication Publication Date Title
JP2017522888A5 (cg-RX-API-DMAC10.html)
JP2022088627A (ja) 多重特異性および多機能性分子ならびにその使用
JP2020122013A5 (cg-RX-API-DMAC10.html)
JP2023100868A (ja) 骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用
JP2022523197A (ja) Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
CN110520445B (zh) 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备
JP2022521750A (ja) カルレティキュリンに結合する多機能性分子およびその使用
CN112955465A (zh) 抗tcr抗体分子及其用途
JP2020023523A5 (cg-RX-API-DMAC10.html)
WO2020094834A1 (en) Il2rbeta/common gamma chain antibodies
EP3707162A1 (en) Il2rbeta/common gamma chain antibodies
JP2019531725A (ja) ラムダ及びカッパ軽鎖を含む多重特異性抗体分子
IL269270B (en) Method and preparations for cellular immunotherapy
JP2019527543A5 (cg-RX-API-DMAC10.html)
CA3164972A1 (en) Materials and methods for in vivo biological targeting
JP2019536430A5 (cg-RX-API-DMAC10.html)
TW201815825A (zh) 經修飾之抗原結合fab片段及包含其之抗原結合分子
JP2019530431A5 (cg-RX-API-DMAC10.html)
JP2018512856A5 (cg-RX-API-DMAC10.html)
JP2024515591A (ja) Ｔｃｒに結合する多機能性分子およびその使用
CN115397852B (zh) 工程化抗il-2抗体
JP2018521691A5 (cg-RX-API-DMAC10.html)
CN121779568A (zh) 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
TW202233674A (zh) 用於調節δγ鏈介導之免疫的組成物及方法
JP2025536908A (ja) Ｔｃｒに結合する多機能性分子およびその使用